Search results
Showing 331 to 345 of 1107 results for infections
Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)
This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.
This quality standard covers routine postnatal care in the first 8 weeks after birth. It describes high-quality care in priority areas for improvement.
View quality statements for QS37Show all sections
Sections for QS37
- Quality statements
- Quality statement 1: Communication between healthcare professionals at transfer of care
- Quality statement 2: Information and advice about babies' feeding
- Quality statement 3: Symptoms and signs of illness in babies
- Quality statement 4: Face-to-face feeding support
- Quality statement 5: Safer practices for bed sharing
- Quality statement 6: GP postnatal check for women
- Quality statement 7: Advice on introducing solid food
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.
Evidence-based recommendations on translaryngeal tracheostomy (TLT). This involves passing a tube from inside the windpipe to outside the neck to aid breathing.
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)
Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults.
Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment (HTG759)
Late stage assessment (LSA) guidance on bed frames for adults in acute medical or surgical hospital wards.
This guideline covers diagnosing and managing drug allergy in all age groups. It aims to make it easier for professionals to tell when someone is having an allergic reaction, by specifying the key signs and patterns to look out for. It also makes recommendations on improving people’s understanding of their drug allergies, and ensuring these are recorded properly in their medical records.
Deep brain stimulation for refractory chronic pain syndromes (excluding headache) (HTG253)
Evidence-based recommendations on deep brain stimulation for refractory chronic pain syndromes (excluding headache). This involves stimulating a precise area of the brain using an electrode to treat the chronic pain.
View recommendations for HTG253Show all sections
Sections for HTG253
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)
Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.
Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.
Leadless cardiac pacemaker implantation for bradyarrhythmias (HTG770)
Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias. This involves implanting a cardiac pacemaker that does not have leads directly into the internal wall of the heart.
View recommendations for HTG770Show all sections
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)
Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)
Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin for people with mild chronic hepatitis C.
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.